Navigation Links
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
Date:11/29/2011

NEW YORK, Nov. 29, 2011 /PRNewswire/ -- Senesco Technologies, Inc. (NYSE AMEX: SNT) announced that that Leslie J. Browne, Ph.D., President and CEO, will present at RetailInvestorConferences.com.

DATE: December 1, 2011
TIME: 10:00 AM EST
LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Senesco recently initiated patient dosing at the Mayo Clinic in Rochester, MN, in a Phase 1b/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma, and also indicated its plan to initiate in 2012 an additional clinical study of SNS01-T in other B-cell cancers. The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models. Potential additional effectiveness was observed from in vitro studies in which SNS01-T was combined with other approved myeloma drugs. "We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNS01-T," stated Leslie J. Browne, Ph.D., President and CEO of Senesco. "Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies."

About Multiple Myeloma

Multiple myeloma is an incurable cance
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
4. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
5. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
6. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
7. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
8. ArborGen and Senesco Announce Wood Quality Results
9. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
10. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
11. Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 2014 ... Sulphate Industry” is a professional and in-depth research ... introduces Potassium Sulphate basic information, including its ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... special dividend payment of $0.50 per share to all stockholders ... record date. As previously announced, the conversion ... 15, 2012 was adjusted to 140.571 shares of common stock ...
... 1 Biotech posted its strongest monthly and quarterly performance ... September rally for equities in more than 70 years. The ... and 13 percent in the third quarter. The Dow Jones ... appreciation during what historically has been a bad month for ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 3Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 4
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
(Date:7/24/2014)... /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative technology ... emergency room wait times by an average of 92 ... according to a recent study published in the Academic ... the suite to access data from incoming patients, implanted ... "Using Geneva,s technology platform we have been able to ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... to develop and evaluate new tools to control the ... five year, 12 million project involving sixteen partners in ... Framework programme. Because malaria is transmitted by mosquitoes, ... Wide scale use of insecticides on bednets and ...
... has long been used as a crop fertilizer, but the ... in manure is ever present. The ratio of nitrogen to ... needs of most crops. Therefore, crops tend to be overloaded ... but the excess phosphorus from the process can damage the ...
... "The rapid translation of biologically-based laboratory discoveries into daily ... trip back from the clinic to the laboratory, to ... behavior. It is imperative for basic researchers to understand ... the knowledge and skills to integrate and use new ...
Cached Biology News:€12 million ($16.9 million) project to develop new tools for malaria control 2
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: